Related Experiment Video
Updated: Mar 30, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Two cases of long-acting paliperidone in adolescence
Marina Fàbrega1, Gisela Sugranyes2, Inmaculada Baeza2
1Department of Psychiatry and Psychology, Hospital Clínic de Barcelona, Carrer Villarroel 170, 08036 Barcelona, Spain.
Abstract:
Paliperidone palmitate long-acting injection (PPLAI) is an atypical antipsychotic agent currently approved by the European Medicine Agency for the acute and maintenance treatment of schizophrenia in adults. However, there is no information so far on safety and effectiveness in patients under 18 years of age. We report on two clinical cases of adolescents with a psychotic spectrum disorder treated with PPLAI in an inpatient setting. The cases illustrate that PPLAI may hold potential as an effective and acceptably tolerated antipsychotic drug in adolescents with psychotic spectrum disorders. Given the lack of approved long acting injectable antipsychotics in patients under 18 years of age, reports on the effectiveness and safety of such medications in children and adolescent patients are of importance.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Cognitive Development During Adolescence
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

